Madrigal Pharmaceuticals Inc. (MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis, is on the verge of a crucial event this week.
Non-alcoholic steatohepatitis, or NASH, a more advanced form of non-alcoholic fatty liver disease, is a leading cause of liver related mortality. People with NASH have an increased risk of heart attack, stroke and death. There are no FDA-approved treatments for the disease, yet.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.